← Back to patent-cliff list
醋酸巴多昔芬
Tier C — Watch / tradeBazedoxifene Acetate
辉瑞
Originator
2009
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ERs
Brand：Viviant、Conbriza
Indications (approved)：绝经期后骨质疏松
Regional status
US
临床二期
2021-12-14
EU
批准上市
2009-04-17
China
无进展
2006-05-01
Japan
批准上市
2010-07-23
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bazedoxifene Acetate?
Approved indications include: 绝经期后骨质疏松.
When does the Bazedoxifene Acetate patent expire?
No public expiry year is available for Bazedoxifene Acetate yet; this page updates once verified.
How do I get a quote for Bazedoxifene Acetate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25